Authors
Annemarie MJ Wensing, David A Van De Vijver, Gioacchino Angarano, Birgitta Åsjö, Claudia Balotta, Enzo Boeri, Ricardo Camacho, Maire-Laure Chaix, Dominique Costagliola, Andrea De Luca, Inge Derdelinckx, Zehava Grossman, Osamah Hamouda, Angelos Hatzakis, Robert Hemmer, Andy Hoepelman, Andrzej Horban, Klaus Korn, Claudia Kücherer, Thomas Leitner, Clive Loveday, Eilidh MacRae, Irina Maljkovic, Carmen De Mendoza, Laurence Meyer, Claus Nielsen, Eline L Op de Coul, Vidar Ormaasen, Dimitris Paraskevis, Luc Perrin, Elisabeth Puchhammer-Stöckl, Lidia Ruiz, Mika Salminen, Jean-Claude Schmit, Francois Schneider, Rob Schuurman, Vincent Soriano, Grzegorz Stanczak, Maja Stanojevic, Anne-Mieke Vandamme, Kristel Van Laethem, Michela Violin, Karin Wilbe, Sabine Yerly, Maurizio Zazzi, Charles A Boucher
Publication date
2005/9/15
Journal
The Journal of infectious diseases
Volume
192
Issue
6
Pages
958-966
Publisher
The University of Chicago Press
Description
BackgroundInfection with drug-resistant human immunodeficiency virus type 1 (HIV-1) can impair the response to combination therapy. Widespread transmission of drug-resistant variants has the disturbing potential of limiting future therapy options and affecting the efficacy of postexposure prophylaxis
penta increase-spacing 1>MethodsWe determined the baseline rate of drug resistance in 2208 therapy-naive patients recently and chronically infected with HIV-1 from 19 European countries during 1996–2002
ResultsIn Europe, 1 of 10 antiretroviral-naive patients carried viruses with ⩾1 drug-resistance mutation. Recently infected patients harbored resistant variants more often than did chronically infected patients (13.5% vs. 8.7%; P=.006). Non-B viruses (30%) less frequently carried resistance mutations than did subtype B viruses (4.8% vs. 12.9%; P<.01). Baseline resistance increased …
Total citations
Scholar articles
AMJ Wensing, DA Van De Vijver, G Angarano, B Åsjö… - The Journal of infectious diseases, 2005